2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Harmful

Warning

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Identifiers

IUPAC Name

(2S,3R)-2-amino-3-[(2-methylpropan-2-yl)oxy]butanoic acid

InChIKey

NMJINEMBBQVPGY-RITPCOANSA-N

SMILES

C[C@H]([C@@H](C(=O)O)N)OC(C)(C)C

Synonyms (15)

H-Thr(tBu)-OH
Linaclotide Impurity 25
O-t-Butyl-L-threonine
O-tert-Butyl-L-allo-threonine
O-tert-Butyl-L-threonine
O-tert.-Butylthreonin
Threonine tert-butyl ether

Sourcing (2S,3R)-2-Amino-3-(tert-butoxy)butanoic acid?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request Supplier? List your product for this CAS

(2S,3R)-2-Amino-3-(tert-butoxy)butanoic acid

Related Compounds

Related Reading

Safety Reference